DANAHER CORP /DE/
DHRAPI behind this page
DHR Q2 2025 request
Playground key active
/api/financials?ticker=DHR&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 5,936 | 5,743 | +3.4% |
Show Product Lines breakouts |
|||
| Nonrecurring revenue | 966 | 1,054 | -8.3% |
| Nonrecurring revenue · Biotechnology | 156 | 235 | -33.6% |
| Nonrecurring revenue · Diagnostics | 247 | 257 | -3.9% |
| Nonrecurring revenue · Life Sciences | 563 | 562 | +0.2% |
| Recurring revenue | 4,970 | 4,689 | +6.0% |
| Recurring revenue · Biotechnology | 1,694 | 1,478 | +14.6% |
| Recurring revenue · Diagnostics | 2,062 | 2,003 | +2.9% |
| Recurring revenue · Life Sciences | 1,214 | 1,208 | +0.5% |
Show Business Segments breakouts |
|||
| Biotechnology · High-growth markets | 448 | 458 | -2.2% |
| Biotechnology · North America | 612 | 607 | +0.8% |
| Biotechnology · Operating Segments | 1,850 | 1,713 | +8.0% |
| Biotechnology · Other developed markets | 82 | 81 | +1.2% |
| Biotechnology · Western Europe | 708 | 567 | +24.9% |
| Diagnostics · High-growth markets | 746 | 743 | +0.4% |
| Diagnostics · North America | 1,064 | 1,042 | +2.1% |
| Diagnostics · Operating Segments | 2,309 | 2,260 | +2.2% |
| Diagnostics · Other developed markets | 94 | 95 | -1.1% |
| Diagnostics · Western Europe | 405 | 380 | +6.6% |
| Life Sciences · High-growth markets | 503 | 495 | +1.6% |
| Life Sciences · North America | 762 | 785 | -2.9% |
| Life Sciences · Operating Segments | 1,777 | 1,770 | +0.4% |
| Life Sciences · Other developed markets | 118 | 116 | +1.7% |
| Life Sciences · Western Europe | 394 | 374 | +5.3% |
Show Geography breakouts |
|||
| High-growth markets | 1,697 | 1,696 | +0.1% |
| North America | 2,438 | 2,434 | +0.2% |
| Other developed markets | 294 | 292 | +0.7% |
| Western Europe | 1,507 | 1,321 | +14.1% |
| Cost of Revenue | -2,413 | -2,315 | -4.2% |
| Gross Profit | 3,523 | 3,428 | +2.8% |
| Selling, General & Administrative | -2,360 | -1,869 | -26.3% |
| Research & Development | -403 | -391 | -3.1% |
| Operating Income | 760 | 1,168 | -34.9% |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 531 | 462 | +14.9% |
| Diagnostics · Operating Segments | 554 | 556 | -0.4% |
| Life Sciences · Operating Segments | -239 | 233 | -202.6% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -86 | -83 | -3.6% |
| Other Non-Operating Income (Expense) | -42 | -59 | +28.8% |
| Interest Expense | -71 | -65 | -9.2% |
| Interest Income | 8 | 39 | -79.5% |
| Income Before Taxes | 655 | 1,083 | -39.5% |
| Income Tax Expense (Benefit) | -100 | -176 | +43.2% |
| Net Income | 555 | 907 | -38.8% |
Show Equity Components breakouts |
|||
| Retained Earnings | 555 | 907 | -38.8% |
| EPS (Basic) | 0.77 | 1.23 | -37.4% |
| EPS (Diluted) | 0.77 | 1.22 | -36.9% |
| Wtd Avg Shares (Basic) | 716.5 | 737.6 | -2.9% |
| Wtd Avg Shares (Diluted) | 719.1 | 742.4 | -3.1% |
| Comprehensive Income | 1,598 | 1,060 | +50.8% |
| Gain Loss On Investments | -44 | -59 | +25.4% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,957 | 2,374 | +24.6% |
| Accounts Receivable | 3,564 | 3,298 | +8.1% |
| Inventory Finished Goods Net Of Reserves | 1,383 | 1,352 | +2.3% |
| Inventory Work In Process Net Of Reserves | 525 | 491 | +6.9% |
| Inventory Raw Materials Net Of Reserves | 781 | 828 | -5.7% |
| Inventory | 2,689 | 2,671 | +0.7% |
| Prepaid Expenses & Other Current Assets | 1,789 | 1,266 | +41.3% |
| Total Current Assets | 10,999 | 9,609 | +14.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 5,309 | 4,643 | +14.3% |
| Other Non-Current Assets | 3,692 | 3,953 | -6.6% |
| Goodwill | 42,991 | — | — |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 23,139 | — | — |
| Diagnostics · Operating Segments | 6,971 | — | — |
| Life Sciences · Operating Segments | 12,881 | — | — |
Show Range breakouts |
|||
| Maximum | 23.1 | — | — |
| Minimum | 1.2 | — | — |
| Total Assets | 81,620 | — | — |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 37,562 | — | — |
| Diagnostics · Operating Segments | 14,537 | — | — |
| Life Sciences · Operating Segments | 23,397 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 6,124 | — | — |
| Operating Lease Right-of-Use Assets | 1.1 | 1.1 | 0.0% |
| Intangible Assets (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Life Sciences · Trade Names | 76 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 18,629 | 19,545 | -4.7% |
| Current Liabilities | |||
| Debt Current | 502 | 701 | -28.4% |
| Accounts Payable Trade Current | 1,725 | 1,645 | +4.9% |
| Accrued Liabilities | 4,565 | 4,355 | +4.8% |
| Total Current Liabilities | 6,792 | 6,701 | +1.4% |
| Non-Current Liabilities | |||
| Other Non-Current Liabilities | 5,633 | 5,643 | -0.2% |
| Long-Term Debt | 16,853 | — | — |
Show Debt Instrument breakouts |
|||
| Euro Denominated Commercial Paper and 2026 Biopharma Euro Notes | 2.6 | — | — |
| Long-Term Debt | 17,355 | 17,010 | +2.0% |
Show Debt Instrument breakouts |
|||
| 0.2% senior notes due 2026 · Senior Notes | 1,463 | 1,336 | +9.5% |
| 0.3% senior notes due 2027 · Senior Notes | 213 | 191 | +11.5% |
| 0.45% senior notes due 2028 · Senior Notes | 1,460 | 1,333 | +9.5% |
| 0.65% senior notes due 2032 · Senior Notes | 367 | 329 | +11.6% |
| 0.75% senior notes due 2031 · Senior Notes | 2,042 | 1,866 | +9.4% |
| 1.125% senior bonds due 2028 · Bonds | 264 | 236 | +11.9% |
| 1.2% senior notes due 2027 · Senior Notes | 701 | 641 | +9.4% |
| 1.35% senior notes due 2039 · Senior Notes | 1,451 | 1,325 | +9.5% |
| 1.8% senior notes due 2049 · Senior Notes | 870 | 795 | +9.4% |
| 2.1% senior notes due 2026 · Senior Notes | 936 | 855 | +9.5% |
| 2.5% senior notes due 2030 · Senior Notes | 937 | 857 | +9.3% |
| 2.6% senior notes due 2029 · Senior Notes | 797 | 797 | 0.0% |
| 2.6% senior notes due 2050 · Senior Notes | 982 | 982 | 0.0% |
| 2.8% senior unsecured notes due 2051 · Senior Notes | 985 | 985 | 0.0% |
| 3.25% senior notes due 2039 · Senior Notes | 892 | 891 | +0.1% |
| 3.35% senior notes due 2025 · Senior Notes | 500 | 499 | +0.2% |
| 3.4% senior notes due 2049 · Senior Notes | 890 | 890 | 0.0% |
| 4.375% senior notes due 2045 · Senior Notes | 500 | 499 | +0.2% |
| Euro-denominated commercial paper · Commercial Paper | 932 | 929 | +0.3% |
| Other | 14 | 8 | +75.0% |
| Stockholders' Equity | |||
| Common Stock | 9 | 9 | 0.0% |
| Additional Paid In Capital Common Stock | 16,960 | 9,806 | +73.0% |
| Treasury Stock Common Value | -9,305 | — | — |
| Retained Earnings | 45,239 | 42,673 | +6.0% |
| Accumulated Other Comprehensive Income | -569 | — | — |
| Total Stockholders' Equity | 52,334 | 49,897 | +4.9% |
| Minority Interest | 8 | 5 | +60.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 52,342 | 49,902 | +4.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -297 | -397 | +25.2% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 155 | 79 | +96.2% |
| Accumulated Other Comprehensive Income | -569 | -2,591 | +78.0% |
| Accumulated Translation Adjustment | -427 | -2,273 | +81.2% |
| Additional Paid In Capital | 16,960 | 16,490 | +2.9% |
| Common Stock | 9 | 9 | 0.0% |
| Noncontrolling Interest | 8 | 5 | +60.0% |
| Retained Earnings | 45,239 | 42,673 | +6.0% |
| Treasury Stock Common | -9,305 | -6,684 | -39.2% |
| Total Liabilities & Equity | 81,620 | 78,555 | +3.9% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 366 | 357 | +2.5% |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 72 | 77 | -6.5% |
| Diagnostics · Operating Segments | 200 | 197 | +1.5% |
| Life Sciences · Operating Segments | 90 | 79 | +13.9% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 4 | 4 | 0.0% |
| Amortization Of Intangible Assets | 836 | 809 | +3.3% |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 441 | 432 | +2.1% |
| Diagnostics · Operating Segments | 96 | 96 | 0.0% |
| Life Sciences · Operating Segments | 299 | 281 | +6.4% |
| Stock-Based Compensation | 152 | 147 | +3.4% |
| Investment Gains Losses And Pretax Gain On Sale Of Product Line | 125 | 96 | +30.2% |
| Asset Impairment Charges | 447 | — | — |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 15 | — | — |
| Life Sciences · Operating Segments | 432 | — | — |
| Life Sciences · Trade Names | 432 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Building | 15 | — | — |
| Change in Accounts Receivable | 134 | 590 | -77.3% |
| Change in Inventory | -248 | -152 | -63.2% |
| Change in Accounts Payable | -111 | -104 | -6.7% |
| Change in Prepaid & Other Assets | -99 | 215 | -146.0% |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | -474 | -822 | +42.3% |
| Net Cash from Operations | 2,637 | 3,156 | -16.4% |
| Investing Activities | |||
| Capital Expenditures | -493 | -578 | +14.7% |
| Proceeds From Sale Of Property Plant And Equipment | 10 | 1 | +900.0% |
| Payments To Acquire Investments | -50 | -127 | +60.6% |
| Proceeds From Sale Maturity And Collections Of Investments | 10 | 9 | +11.1% |
| Proceeds From Sale Of Product Line | 9 | — | — |
| Other Investing Activities | 14 | 26 | -46.2% |
| Net Cash from Investing | -500 | -681 | +26.6% |
| Financing Activities | |||
| Payments For Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 14 | 76 | -81.6% |
| Payments Of Dividends | -423 | -377 | -12.2% |
| Proceeds From Debt Maturing In More Than Three Months | 4 | — | — |
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | -1 | 15 | -106.7% |
| Share Repurchases | -1,078 | -4,530 | +76.2% |
| Proceeds From Payments For Other Financing Activities | -18 | -58 | +69.0% |
| Net Cash from Financing | -1,502 | -5,848 | +74.3% |
| Supplemental | |||
| Interest Paid | 149 | 176 | -15.3% |
| Income Taxes Paid | 531 | 618 | -14.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 244 | -117 | +308.5% |
| Net Change in Cash | 879 | -3,490 | +125.2% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.